What is Newomics?
Newomics operates at the intersection of biotechnology and precision instrumentation, specializing in high-performance devices that enhance the sensitivity and throughput of LC-MS workflows. Their core product suite, including the UniESI system and MEA chip, provides plug-and-play compatibility for complex analytical tasks. By addressing critical bottlenecks in metabolomics, proteomics, and clinical biomarker discovery, Newomics serves a diverse client base ranging from drug development laboratories to environmental monitoring agencies. The company's commitment to robust, scalable multiomics solutions establishes it as a key infrastructure provider in the modern life sciences ecosystem.
How much funding has Newomics raised?
Newomics has raised a total of $11.9M across 3 funding rounds:
Series A
$3.9M
Debt
$150K
Series B
$7.9M
Series A (2018): $3.9M with participation from Undisclosed
Debt (2020): $150K led by PPP
Series B (2020): $7.9M supported by Photon Fund, MSA Capital, LDV Partners, and Berkeley Catalyst Fund
Key Investors in Newomics
MSA Capital
Founded in 2014, MSA Capital is an independent global private equity and venture capital firm with over $1.5 billion under management. MSA actively partners with outstanding entrepreneurs globally to build leading, innovative companies that aim to deliver strong financial returns and meaningful, positive social impacts.
LDV Partners
LDV Partners is dedicated to transforming innovative ideas into successful companies by collaborating closely with visionary founders. They provide strategic insights, hands-on support, and essential resources to foster growth in disruptive technologies, with a focus on AI and life sciences.
Berkeley Catalyst Fund
Berkeley Catalyst Fund is a venture capital firm based in Cupertino, California, that provides essential financial benefits and operational support to entrepreneurial startups in the science and technology sectors.
What's next for Newomics?
With the recent infusion of capital, Newomics is expected to prioritize the expansion of its commercial footprint and the further refinement of its multiomics platform. The strategic focus will likely center on deepening market penetration within clinical diagnostics, where the demand for high-sensitivity mass spectrometry is rapidly increasing. Furthermore, the company is well-positioned to leverage its investor network to forge partnerships that facilitate the integration of its technology into global drug development pipelines. As the industry shifts toward more granular molecular analysis, Newomics' ability to maintain high-throughput performance will be the primary driver of its long-term market valuation and competitive advantage.
See full Newomics company page
